Brainstorm Cell Therapeutics Inc. (BCLI) Financials

BCLI Assets vs Liabilities
DateAssetsLiabilities
March 31, 2026 571000 11.8 million
Dec. 31, 2025 715000 11.0 million
Sept. 30, 2025 1.4 million 9.1 million
June 30, 2025 2.6 million 8.6 million

BCLI Free Cash Flow and Stock based compensation
Graph available only for paid members. Upgrade to see it.
DateFree Cash FlowStock based compensation
March 31, 2026 -1.3 million 133000
Dec. 31, 2025 -740000 143000
Sept. 30, 2025 -1.1 million 157000
June 30, 2025 -3.5 million 503000

BCLI Net Income

No data available :(

BCLI Cash and Debt
Graph available only for paid members. Upgrade to see it.
DateCashDebtCapital Lease
March 31, 2026 15000 - -
Dec. 31, 2025 29000 208000 208000
Sept. 30, 2025 5000 - 50000
June 30, 2025 824000 - 476000

BCLI Shares Outstanding
Graph available only for paid members. Upgrade to see it.
DateShares Outstanding
March 31, 2026 11.0 million
Dec. 31, 2025 9.3 million
Sept. 30, 2025 11.0 million
June 30, 2025 8.6 million

BCLI Expenses
Graph available only for paid members. Upgrade to see it.
DateCapexR&DG&AS&M
March 31, 2026 - 725000 1.3 million -
Dec. 31, 2025 - -3.3 million -4.4 million -
Sept. 30, 2025 - 899000 1.1 million -
June 30, 2025 - 1.1 million 1.5 million -

BCLI Cost of Revenue
Graph available only for paid members. Upgrade to see it.
DateRevenueCost of Revenue
March 31, 2026 178000 37000
Dec. 31, 2025 703000 48000
Sept. 30, 2025 - -
June 30, 2025 - -

BCLI

Price: $0.86

52 week price:
0.46
1.33

Earnings Per Share: -0.85 USD

Exchange: NCM

Sector: Healthcare

Industry: Biotechnology

Country: United States

Volume: 566900

Ebitda: -2.4 million

Market Capitalization: 8.7 million

Links: